Article processing charges (APCs) support peer review coordination, editorial management, production, DOI registration, and long term digital archiving. APCs are applied after acceptance and do not influence editorial decisions.

JFB is committed to transparency and affordability for fertility biomarker research communities.

• Editorial assessment and peer review management
• Copyediting, layout, and publication production
• DOI registration and metadata validation
• Long term archiving and platform maintenance
• Open access hosting and global dissemination

Authors from World Bank classified low income and lower middle income countries may be eligible for partial APC waivers. Requests are evaluated on a case by case basis and must be submitted before acceptance.

Membership options offer discounted APCs for eligible authors and institutions. Contact the editorial office for guidance.

Many reproductive medicine teams publish under grant or institutional mandates. Share funder requirements early so the editorial office can align invoicing and reporting needs.

• Provide grant identifiers and funding statements
• Confirm open access mandates or repository requirements
• Share billing contacts for institutional or funder payments
• Document any reporting deadlines tied to publication
• If your institution requires invoice language or grant identifiers, provide them before acceptance to avoid delays.
• APC receipts include journal name, manuscript title, and DOI reference for institutional reporting.
• Payment can be made by institutions, funders, or authors. Coordinate billing details early to streamline processing.
• Requests for partial waivers should be submitted before acceptance with supporting documentation.
• APCs support long term digital preservation and open access distribution of fertility biomarker research.
• If a funding agency requires open access confirmation, the editorial office can provide verification after publication.
• Invoices can be issued to a central grants office when funding sources require consolidated billing.
• APC questions are handled by the editorial office; contact them early to align budgets with publication timelines.
• Provide billing contacts and purchase order details early to avoid administrative delays during production.
• Institutions covering APCs should confirm currency conversion requirements and tax exemptions if applicable.
• Waiver requests should include a brief justification and confirmation of eligibility criteria.
• If funding is pending, notify the editorial office so invoice timelines can be coordinated.
• Payment confirmations are required before copyediting and proof preparation begin.
• For multicenter studies, designate a single billing contact responsible for APC coordination.
• Define the primary biomarker category (hormonal, imaging, genomic, proteomic, or metabolomic).
• Report assay platform, manufacturer, and kit lot numbers where applicable.
• Provide sample collection timing relative to cycle day or stimulation phase.
• Describe specimen type and handling conditions (serum, plasma, follicular fluid, semen).
• Include storage temperature, freeze thaw cycles, and transport timelines.
• Provide calibration procedures and quality control ranges.
• Report intra assay and inter assay variability.
• Specify detection limits and linearity ranges for biomarker assays.
• Use standardized units and reference ranges for all biomarkers.
• Define cohort inclusion and exclusion criteria in detail.
• Report infertility diagnosis categories (PCOS, endometriosis, male factor, unexplained).
• Describe ovarian reserve markers measured (AMH, FSH, AFC).
• Provide ultrasound methodology and counting criteria for AFC.
• Report hormonal assay timing (follicular, luteal, trigger day).
• Describe stimulation protocol details and medications.
• Provide number of oocytes retrieved and maturity rates.
• Report fertilization method (IVF or ICSI).
• Provide embryo grading criteria and day of assessment.
• Include morphokinetic parameters if time lapse imaging is used.
• Report PGT methods and indications when relevant.
• Describe endometrial assessment method and timing.
• Define implantation, clinical pregnancy, and live birth outcomes.
• Report miscarriage and obstetric outcome definitions.
• Include male factor biomarker measures (DNA fragmentation, ROS, motility).
• Provide semen analysis standards and WHO reference criteria.
• Report abstinence period for semen samples.
• Describe laboratory equipment and imaging settings.
• Provide statistical power and sample size justification.
• Adjust for confounders such as age, BMI, and smoking.
• Report handling of repeated cycles per patient.
• Describe blinding and randomization when applicable.
• Provide missing data handling and sensitivity analyses.
• Include external validation or replication cohorts.
• Provide model performance metrics for predictive tools.
• Report calibration and discrimination metrics for models.
• Describe feature selection and preprocessing steps for omics data.
• Provide batch effect correction methods for omics datasets.
• State ethics approvals and consent procedures.
• Provide data availability statements and repository links.
• Describe clinical decision thresholds for biomarker adoption.
• Report cost or resource implications when relevant.
• Include patient reported outcomes when collected.
• Describe geographic and demographic diversity of the cohort.
• Report laboratory accreditation status when applicable.
• Provide assay cross reactivity information.
• Describe quality assurance procedures in the lab.
• Report time from sample collection to analysis.
• Include details on environmental or lifestyle covariates.
• Describe ovarian stimulation response metrics.
• Report luteal phase support regimens when applicable.
• Include details on cryopreservation methods.
• Report embryo transfer protocols (fresh vs frozen).
• Provide endometrial thickness measurement technique.
• Describe imaging interpretation criteria for biomarkers.
• Report follow up duration for outcomes.
• Include limitations regarding generalizability.
• Provide clinical utility statements for biomarker adoption.
• Report multi omics integration methods when used.

To avoid delays, payments should be completed within 48 hours of invoice receipt. Publication proceeds after payment confirmation.

JFB is committed to rigorous, transparent publishing in fertility biomarker research and reproductive medicine. We emphasize reproducible laboratory methods, clear reporting of diagnostic criteria, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in biomarker validation, reproductive outcomes, and translational fertility science.